Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abatacept

- PMLiVE

BMS, Exelixis and Ipsen report three-year results for combination treatment in kidney cancer

Renal cell carcinoma accounts for more than 431,000 new cases and 179,000 deaths each year

- PMLiVE

BMS and 2seventy bio report positive phase 3 results for multiple myeloma treatment

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP

At least 100 million people worldwide are impacted by some form of psoriasis

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

- PMLiVE

BMS’s Reblozyl meets primary endpoint in myelodysplastic syndromes phase 3 trial

The study showed significant improvements in red blood cell transfusion independence

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival

- PMLiVE

Bristol Myers Squibb’s active ulcerative colitis treatment bags NICE recommendation

Phase 3 trial results of Zeposia showed statistically significant results in response and remission

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

A phase 3 trial demonstrated a statistically significant benefit in recurrence-free survival versus placebo

- PMLiVE

Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE

Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival

- PMLiVE

Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics

The deal offers BMS a pipeline of investigational medicines to expand its oncology portfolio, including repotrectinib

- PMLiVE

Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies

The companies will work together to develop new therapies to re-establish immune tolerance and repair tissue for those with inflammatory bowel diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links